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ABSTRACT 
Background  
Systemic sclerosis (SSc) is a chronic systemic autoimmune disease primarily affecting skin and 
internal organs. It is characterized by excessive fibrosis, vasculopathy and chronic inflammation. 
The disease is associated with increased morbidity and mortality, but to date, there have been no 
studies on causes of death and predictors thereof in Sub-Saharan Africa. 
Objective  
To determine the spectrum of causes of death in SSc patients attending the Connective Tissue 
Disease Clinic at the Chris Hani Baragwanath Academic Hospital.   
Methods 
A retrospective record review of patients meeting the ACR/EULAR (full criteria attending the 
Connective Tissue Disease Clinic at Chris Hani Baragwanath Academic Hospital between Jan 
1990 to Dec 2015).  
Results 
Of the 282 records reviewed, 174 patients met the inclusion criteria. The majority of patients 
were Black African (92.5%), with a female to male ratio of 7:1. The mean (SD) age at diagnosis 
and follow up period were 41.8 (13.1) years and 65.8 (66.4) months respectively at last visit. 
Only 53 were known to be alive at the end of the study, 63 were lost and/or could not be found 
during follow-up, and there were 58 known deaths. The major known causes of death were 
disease-related: cardiopulmonary in 24 (41.4%) and SRC in 1 patient (1.7%). The disease-
unrelated causes included infection in 5 patients (8.6%) and malignancy in 2 patients (3.5%). 
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Predictors of mortality included serositis, renal dysfunction, digital ulcers, proteinuria, and a 
raised C-reactive protein (CRP). The estimated survival rates were 56.3% at 5 years and 35.8% 
at 10 years –  censored for patients lost to follow up. 
Conclusion 
In the present study, SSc was associated with a high morbidity and mortality especially 
cardiorespiratory complications. The cause of death in our study was predominantly disease 
related, which is in accordance with that reported in other studies. Cardiopulmonary causes 
remain the leading causes of death in our population comparable to that reported in studies done 
in other countries. 
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CHAPTER ONE: LITERATURE REVIEW 
1.1 Definition 
Systemic sclerosis (SSc), also known as scleroderma, is a chronic systemic autoimmune disease 
primarily affecting the skin and internal organs (Rodnan and Benedek 1962). It is characterized 
by vascular abnormalities, fibrosis, inflammation and atrophy of the skin and internal organs 
(Czirjak, Foeldvari et al. 2008) . In 1988, formal definitions of subsets were described. These 
include diffuse cutaneous SSc (dcSSc), limited cutaneous SSc (lcSSc), SSc sine scleroderma, 
environmentally-induced SSc, and overlap syndromes (LeRoy, Black et al. 1988). Evidence of 
diffuse cutaneous SSc is skin thickening that extends from the digits proximally to the elbows 
and/or knees. This subset is more likely to be associated with systemic involvement such as renal 
crisis, pulmonary fibrosis and cardiomyopathy. In the case of lcSSc, skin thickening is restricted 
mainly to the fingers, hands and forearms, and is associated with less involvement of internal 
organs except for pulmonary hypertension (Meyer, Fertig et al. 2007). Systemic sclerosis sine 
scleroderma presents with typical organ involvement but with no clinical evidence of skin 
thickening (Molina, 1995). 
1.2 History of systemic sclerosis 
The term scleroderma is derived from the Greek word skleros, meaning hard or indurated, and 
derma, meaning skin (de Silva and Parish 1994). Even though a number of physicians in ancient 
times described patients with hardening of the skin, none of the descriptions were conclusive. 
The closest was a delineation by Hippocrates around 400 BC, who described an Athenian man 
with indurated unpinchable skin (de Silva and Parish 1994). In 1818, Alibert, a French 
dermatologist  commented about SSc as “nothing is more bizarre, but also nothing is more 
interesting than corn degeneration of dermoid system” (Rodnan 1962). Dr Curzio, an Italian 
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doctor, subsequently published the first case report of SSc in 1753, which, to date, is considered 
the first definitive account of the disease. Despite there being some doubts with regards to the 
clinical presentation of the patient, as the clinical features disappeared after 11 months, this is 
still considered a landmark in the discovery and description of the disease (Roberts-Thomson 
and Walker 2006). Following these publications, more clinicians became aware of the condition 
and its clinical manifestations. Thus, several more cases were reported by the late nineteenth 
century physicians (de Silva and Parish 1994). The term scleroderma was later changed to 
progressive systemic sclerosis by a South African pathologist, Dr Goetz, who observed multi 
organ involvement in autopsy studies (de Silva and Parish 1994). Eventually, the term 
“progressive” was removed, as not all cases of SSc were necessarily progressive in nature. 
1.3 Epidemiology 
1.3.1 Global epidemiology 
Different studies done in different countries show variation in the global occurrence of SSc. As 
shown in Table 1, reported prevalence rates vary widely from as low as 30.8 cases per million in 
England, to as high as 658,6 cases per million in the Choctaw Indians of USA (Barnes and 
Mayes 2012). Moreover, the prevalence rates vary by gender and race, with females being 
affected 4 to 5 times more than males and blacks more than whites. Generally, lcSSc is the 
predominant subset in Caucasians and dcSSc in other populations (Joven, Almodovar et al. 
2010). 
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Table 1: Epidemiology of SSc (Barnes and Mayes 2012) 
 
1.3.2 Epidemiology of systemic sclerosis in Africa 
There have been no formal epidemiological studies on the incidence and prevalence rates of SSc 
in Africa. One study in a Kinshasa health care facility reported a 0.6% of rheumatological cases 
seen in a rheumatology clinic (Malemba and Mbuyi-Muamba 2008).  
1.3.3 Environmental risk factors   
Although the exact cause(s) of SSc remain unknown, environmental risk factors contribute to the 
development of the disease. These risk factors are both occupational and non-occupational   
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related. The most well-described occupational risk factor is exposure to silica. A higher 
incidence has been described in gold miners with exposure to silica dust; suggesting a 
contribution of silica in the pathogenesis (Cowie 1987). Some studies have reported the risk of 
developing SSc to be  5 to 6 times higher in people exposed to silica dust compared to the 
general population (Dospinescu, Jones et al. 2013). There is some evidence suggesting a link 
between solvent exposure and early SSc development (Dospinescu, Jones et al. 2013). A study 
carried out in France found that individuals with high cumulative exposure to solvents were 5 
times more likely to develop SSc than the general population (Marie, Gehanno et al. 2014). 
Other studies looking at other occupation exposures such as vibration and fumes have yielded no 
positive association (Dospinescu, Jones et al. 2013). Non-occupational environmental risk 
factors such as smoking and alcohol consumption have also been associated with a higher risk 
for developing SSc. Smoking is thought to have greater impact on disease severity rather than a 
risk factor for developing SSc (Dospinescu, Jones et al. 2013). Other environmental factors 
postulated as contributors to the aetiology of the disease include vinyl chloride, medications such 
as bleomycin, pentazocine, and cocaine, and viruses such cytomegalovirus and parvovirus B19 
(Balbir-Gurman and Braun-Moscovici 2012). These chemicals and microbes are thought to cause 
immunologically mediated vascular injury, inflammation and tissue fibrosis; with the latter being 
the predominate pathological feature of SSc (Saketkoo, Magnus et al. 2014). 
1.4 Genetics risk factors  
Genetic risk factors appear to play less of a role in predisposing SSc compared to other 
connective tissue diseases. Twin studies have shown a poor concordance with disease expression 
but better concordance with autoantibodies (Feghali-Bostwick, Medsger et al. 2003).  Even 
though positive family history is still regarded as one of the strongest genetic risk factor, the   
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actual familial risk is very low (Herrick and Worthington 2002).  The highest incidence of SSc 
has been documented in the Choctaw Indians of North America (Table 1), and is due to a unique 
HLA haplotype (include haplotype) (Arnett, Howard et al. 1996). Like in other autoimmune 
connective tissue diseases,,SSc has been associated with certain HLA class II antigens. 
Principally, HLA DR3 occur more frequently in Caucasion with lcSSc, and HLA DR15 with 
dcSSc in other populations including South Africans (Tikly, Rands et al. 2004). A number of 
non-HLA genes are also known to be associated with scleroderma in Caucasian populations.  
1.5 Aetiopathogenesis  
Although the precise aetiology of the disease remains elusive, there are several lines of evidence 
suggesting that environmental factors in a genetically susceptible host triggers the disease 
process leading to initially vascular abnormalities, followed by immune-mediated chronic 
inflammation and fibrosis of the skin and visceral organs (Charles, Clements et al. 2006) 
1.6 Clinical features and classification criteria  
1.6.1 Clinical features 
Systemic sclerosis has a variable presentation. In patients with DcSSc, there is extensive skin 
involvement and frequent internal organ fibrosis such as interstitial lung disease on the other 
hand in patients with LcSSc, vascular features such as RP or telangiectasia and pulmonary 
arterial hypertension predominate. Whereas LcSSc is the predominate subset in Caucasians, 
DcSSc is seen more often in other populations including Africans (Laing, Gillespie et al. 1997, 
Tager and Tikly 1999).The age of onset is generally lower in DcSSc compared to LcSSc  (Steen, 
Domsic et al. 2012).  
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The most common clinical manifestation of SSc is Raynaud’s phenomenon (RP), with more than 
90% of patients reported to have RP at presentation (Meier, Frommer et al. 2012). It symbolizes 
one of the early signs of presentation of the disease. With time, RP can progress to an 
exaggerated form of vasculopathy, presenting in the form of digital ulcers and digital gangrene. 
Cutaneous manifestations are characterized by skin thickening of the fingers of both hands 
extending proximal to the metacarpophalangeal joints limited to the elbow and knees in LcSSc 
and extending beyond the elbows and knees in dcSSc. Oher manifestations include (“salt and 
pepper pigmentation”), telangiectasia, calcinosis, hypo and hyperpigmentation and nailfold 
capillary changes. The modified Rodnan skin score (mRSS), which looks at the degree of skin 
thickening at different sites of the body, is used as a measure of the extent and severity of skin 
involvement. 
The gastrointestinal manifestations of the disease are common, with most studies reporting a 
frequency of more than 60% (Hesselstrand, Scheja et al. 1998, Meier, Frommer et al. 2012, 
Poormoghim, Moghadam et al. 2013). The disease can affect any part of the gastrointestinal tract 
from the oral cavity to the anus. Dysphagia and reflux are the commonest early symptoms. In 
established cases, patients might develop malabsorption and faecal incontinence.(Tian and Zhang 
2013). 
Renal manifestations are rare  and vary from asymptomatic proteinuria to a severe complication 
like scleroderma renal crisis (SRC), which in a recent study, has been reported to have a 
frequency of 2.1% (Meier, Frommer et al. 2012). Mortality related to SRC has  decreased  
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dramatically in the last three decades mainly due to increased awareness of the complication and 
early intervention of angiotensin converting enzyme inhibitors (ACEI) (Steen and Medsger 
2007).  
Pulmonary manifestations of SSc include pleural effusions, aspiration pneumonia secondary to 
oesophageal dysmotility, interstitial lung disease (ILD) and pulmonary hypertension (PH). 
Systemic sclerosis-related ILD is one of the most common causes of death in SSc (Tyndall, 
Bannert et al. 2010). Pulmonary hypertension can be either secondary to ILD or occur as isolated 
pulmonary arterial hypertension. The latter is a major cause of death in patients with 
longstanding LcSSc. A UK study reported the prevalence of pulmonary hypertension standing at 
12% (Mukerjee, St George et al. 2003).  
The commonest cardiac complication in SSc is cor pulmonale and right heart failure secondary 
to pulmonary hypertension. Primary cardiac involvement is rare and can present as arrhythmias, 
pericardial disease or myocardial involvement (Plastiras and Toumanidis 2012). 
1.6.2 Autoantibody profile 
Systemic sclerosis is associated with several autoantibodies. It is unclear whether these 
antibodies directly contribute to disease process or are a result of the disease pathogenesis itself 
(Ho and Reveille 2003). Up to 90% of patients will have a positive antinuclear test. Several 
specific antinuclear antibodies have been described in SSc. The most common of these are the 
anti-topoisomerase 1 (ATA) (also known as anti-Scl-70), anticentromere and anti-RNA 
polymerase III (Anti-RNAP) antibodies (Salazar, Assassi et al. 2015). 
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Antitopoisomerase-1 antibodies target type 1 topoisomerase; an enzyme responsible for relaxing 
DNA strands within the nucleus. These antibodies are commonly seen in patients with DcSSc 
and ILD. They are also prevalent in some populations like the Japanese and less in Caucasians   
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(Walker and Fritzler 2007, Grassegger, Pohla-Gubo et al. 2008) . Anticentromere antibodies 
occur mostly in Caucasian patients with LcSSc and are rarely seen in Black Africans. (Pudifin, 
Dinnematin et al. 1991). 
These autoantibodies have prognostic implications with the ATA and anti-RNAP carrying the 
worst prognosis and ACA, anti U1 RNP and anti PM Scl associated with a  better prognosis.(Ho 
and Reveille 2003). The ATA, anti–fibrillarin (U3RNP) and anti-RNAP are found mostly in 
DcSSc, whereas ACA, anti-PM Scl, anti-U1RNP and anti –Th/To are found mainly in LcSSc 
(Ho and Reveille 2003).  
1.6.3 Classification criteria 
The first classification criteria for SSc were developed by the American College of 
Rheumatology (ACR). These criteria included skin thickening proximal to the 
metacarpophalangeal joints as the major criterion, and sclerodactyly, digital pitting scars, and 
bibasilar pulmonary fibrosis as the minor criteria. A patient with either the major criteria or 2 of 
3 minor criteria was said to fulfil the criteria for SSc . These criteria were found to be insensitive 
to recognising early disease. In Leroy and Medsger‘s criteria for early diagnosis and 
classification of SSc, they proposed the inclusion of  nailfold capillary changes and SSc-specific 
autoantibodies for the classification of SSC  (LeRoy and Medsger 2001). 
As recent as 2013, the ACR/EULAR classification criteria for SSc were published. These criteria 
include more clinical and serological features which are given different weightings. (van den 
Hoogen, Khanna et al. 2013). Patients with an overall score of 9 or more are deemed to have 
SSc. (see Appendix C)(van den Hoogen, Khanna et al. 2013) . These criteria allow for earlier 
diagnosis of the condition.  
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1.7 Natural history, morbidity and mortality 
1.7.1 Natural history of SSc 
The natural history of the disease shows that there are variations to the disease subset. Patients 
with DcSSc tend to have a more aggressive course with early organ involvement than LcSSc, 
which tends to have a relatively benign course with late onset of complications like pulmonary 
hypertension, as shown in Figure 1  
 
Figure 1:  Natural history of SSc (Steen and Medsger 1990) 
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1.7.2 Trends of mortality in SSc 
Studies from various countries show a wide variation in outcome (Kuwana, Kaburaki et al. 1994, 
Ruangjutipopan, Kasitanon et al. 2002, Hesselstrand, Scheja et al. 2003, Czirjak, Kumanovics et 
al. 2008). In one US centre, the 10-year cumulative survival has improved significantly from 
53% in the 1970s to 67% in the 1990s (Steen and Medsger 2007).  
SSc is associated with high mortality compared to the general population, and in a Swedish 
study, the standardised mortality rate for SSc was found to be 4.6 (Hesselstrand, Scheja et al. 
1998).  Survival rates have been reported to vary by geographical location and disease subset. In 
industrialised countries the average 5 and 10 year survival rates are at best 80% and 70% 
respectively. A 10 year survival rate of 92% in lcSSc versus 65% in dcSSc has been reported in a 
Canadian study (Al-Dhaher, Pope et al. 2010). 
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Table 2: Summary of survival rates in SSc 
Location Year 5 year/ 10 year 
survival (%) 
% dcSSc 
Sweden(Hesselstrand, 
Scheja et al. 1998) 
1998 86/69 25 
Spain(Joven, Almodovar et 
al. 2010) 
2010 85/75 31 
Taiwan(Kuo, See et al. 
2011) 
2011 83.2/- - 
Canada(Al-Dhaher, Pope et 
al. 2010) 
2010 90/82 37 
UK(Bryan, Howard et al. 
1996) 
1996 87/75 46 
Hungary(Czirjak, 
Kumanovics et al. 2008) 
2007 84/72.6 27.6 
Iran(Poormoghim, Andalib 
et al. 2016) 
2016 92.9/82.3 40 
 
There has been a great shift in mortality rates in recent times. Studies have shown substantially 
improved outcomes that can be attributed to early and improved screening of organ involvement. 
The effective management of scleroderma renal crisis with the use of ACEI has resulted in a 
substantial reduction in mortality. Despite this, SSc is still associated with a high mortality as 
shown by the fact that more than half of deaths are directly related to the disease itself (Tyndall, 
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Bannert et al. 2010) (Al-Dhaher, Pope et al. 2010). Survival is significantly low among women 
with diffuse disease with or without organ complication (Laing, Gillespie et al. 1997), and 
survival outcome is also worse in Black patients than Caucasian (Laing, Gillespie et al. 1997). 
1.7.3 Causes of death in SSc 
Causes of death in SSc are generally categorised in to two; those that are directly disease-related 
or disease-unrelated. Disease related causes of death are those that are caused by SSc organ 
involvement, for example pulmonary fibrosis. Deaths due to disease-unrelated causes include 
infections and malignancies. Most deaths are disease-related, with ILD being the most common 
in dcSSc, and PAH in lcSSc (Barnes and Mayes 2012). Moreover, the spectrum of causes of 
death has changed over the last two to three decades in industrialised countries as depicted in 
Figure 2 (Steen and Medsger 2007). This US study showed a significant decline in deaths due to 
SRC over the last 3 decades. Today, pulmonary fibrosis  (ILD) and pulmonary hypertension rank 
as the top causes of death.  
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Figure 2: Changes in the causes of death (Steen and Medsger 2007) 
 
1.7.4 Predictors of mortality in SSc 
Multiple studies have reported on the predictors of survival in SSc. Risk factors that have been 
identified as poor prognostic factors include dcSSc, proteinuria, PAH, FVC<80% of the normal, 
presence of dyspnoea, younger age at onset of RP, low diffusion capacity of the lung for carbon 
monoxide (DLCO) and high modified Rodnan skin score (mRSS). Other predictors of mortality 
that have previously been described include, male gender, an elevated erythrocyte sedimentation 
rate (ESR), earlier age at diagnosis and black ethnicity (Al-Dhaher, Pope et al. 2010). In all these 
predictors, men have a worse prognosis than women (Joven, Almodovar et al. 2010).  
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1.8 Principles of management 
There is currently no single cure for SSc. The approach to management is individualised and 
based on the extent of organ involvement. Management of vascular complications is aimed at 
improving peripheral circulation and reducing PAH. Thus, treatment options include calcium 
channel blockers, prostaglandin analogues, phosphodiesterase 5 inhibitors, and endothelin 
receptor antagonists, alpha-blockers, serotonin inhibitors and angiotensin II receptor inhibitors. 
The mainstay of therapy for the fibrotic complications such as ILD is immunosuppression drugs 
including cyclophosphamide, azathioprine, mycophenolate mofetil and rituximab. Autologous 
haemopoietic stem cell transplantation has been used to treat severe refractory cases in some 
centres. As indicated above ACEI are effective in the management of SSc (Matucci-Cerinic, 
Steen et al. 2007) 
Treatment of GIT complications is mainly symptom based, with use of proton pump inhibitors 
(PPI) for reflux oesophagitis , cauterization or laser probe therapy for gastric antral vascular 
ectasia (GAVE), antibiotic therapy for bacterial overgrowth and the use of high fibre diets and 
laxatives for patients with constipation (Tian and Zhang 2013). 
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Table 3: Summary of therapeutic options (Balbir-Gurman and Braun-Moscovici 2012) 
 
1.9 Aims and objectives of the present study 
The aim of this study was to investigate the spectrum of causes of death in patients with SSc at 
Chris Hani Baragwanath Academic Hospital. The primary objectives were to determine disease-
related and disease unrelated causes of death in SSc. The secondary objectives were to identify  
demographic, clinical and laboratory predictors of death and to estimate the 5 year and 10 year 
survival rates of SSc patients.   
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CHAPTER TWO: PATIENTS AND METHODS 
 2.1 Study design 
A retrospective record review study of clinical records of SSc patients attending the Connective 
Tissue Disease Clinic at Chris Hani Baragwanath Academic Hospital, a tertiary level hospital in 
Soweto (South Western Township) in Gauteng was carried out. This hospital occupies 0.7km² 
(170 acres), with approximately 3200 beds and around 6760 staff members. The facilities are 
housed in 429 buildings with a total surface area of 233759 m². It is the third largest hospital in 
the world serving the community of Soweto, a region in the south of Johannesburg with a 
population of about 1.2 Million.  
Inclusion criteria were patients older than 18 years of age at first diagnosis, fulfilling the 
ACR/EULAR classification criteria for SSc(van den Hoogen, Khanna et al. 2013) , adequate 
clinical records with at least 2 clinic visits, 6 months apart and seen at the Connective Tissue 
Clinic from 1 Jan 1990 to 31 December 2015. Patients who were deemed to have overlap 
connective tissue syndrome and those with inadequate clinical records were excluded from the 
study. . 
2.2 Data variables   
Data variables that were abstracted from clinical records using a prepared data collection sheet 
(see Appendix 1) included demographics such as age, sex, and ethnicity and smoker status, 
disease subset as defined by the Leroy and Medsger criteria (LeRoy, Black et al. 1988), and 
clinical features. The latter included: skin, musculoskeletal, cardiac, respiratory, gastrointestinal 
and renal manifestations of the disease. Laboratory investigations that were captured included: 
haemoglobin (Hb), (ESR), C reactive protein (CRP), complement (C3, C4), creatine kinase (CK) 
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and autoantibodies. The definitions for the clinical data and laboratory data are shown in 
Appendix A.  
Deaths were confirmed from clinical records and the hospital registry. The causes of death were 
based  on available clinical records  and were further divided into those deemed to be directly, 
indirectly or unrelated to SSc. Outcomes were defined as known dead, known alive or lost to 
follow up on 31 December 2015. Survival times were calculated from date of diagnosis to death. 
 
Data was anonymized by allocating each patient a study number so that no personal details of 
individual patients were known. The study was approved by the Human Research Ethics 
Committee (HREC) of the University of the Witwatersrand (Clearance Certificate: Appendix D) 
and conducted in line with the Declaration of Helsinki principles. 
2.3 Statistical methods 
Data were captured on Microsoft excel spreadsheet. It was then imported to a statistical package 
(STATA and Statistica). Univariate statistical analysis was performed applying either the one-
way ANOVA test in the case of continuous variables and chi-square test (with Yates’ correction) 
or Fisher’s exact test for categorical variables. Survival curves were constructed using the 
Kaplan–Meier method. Univariate Cox proportional hazard regression model was applied to 
determine predictors of death. A p-value <0.05 was considered statistically significant. 
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CHAPTER THREE: RESULTS 
3.1 Overview of data analysed 
As shown in Figure 2, of the 291 case records reviewed of patients seen at the Connective Tissue 
Disease clinic during the period 1990 to 2015, 282 fulfilled the criteria for SSc. Thirty patients 
were excluded due to presence of overlap syndrome. A further number of 78 patients were 
excluded due to inadequate data and a follow up duration of less than 6 months. Thus, only 174 
records were included in the final analysis. 
 
Figure 3: Summary of records reviewed  
291 Files analysed
282 Met the SSc 
criteria
252 had NO Overlap 
syndrom
174, follow up ≥ 6 
months
78 excluded due to file 
information missing 
and follow up duration 
of < 6 months
30 Excluded due to 
Overlap syndrom
9 Excluded due to not 
meeting the SSc 
criteria
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3.2 Demographics 
Table 4 shows the demographics of the 174 patients. The majority of the patients were females 
comprising 87.4 % of the cases. The female to male ratio was 7:1. Regarding ethnicity, a large 
proportion (92.5%) of the patients were Black versus 6.9 % belonging to other ethnic groups. 
The mean age at diagnosis was 42 years with a range of 13 years to 73 years. The mean follow 
up duration was 65.8 months. A total number of 128 (73.6%) were classified as DcSSc and 44 
(26.4%) as LcSSc. The number of patients lost to follow up was 63 (36.2%) and the number of 
known deaths was 58, constituting 33.3 % of cases recorded. 
Table 4: Demographical features and outcomes of patients 
    DcSSc(n=128) LcSSc(n=46) All SSc (n=174) 
Gender (F)  108 (71.1%) 44  (96%) 152 (87.4%) 
 F:M  5:1 22:1 7:1 
Ethnic group     
Black  121 (94.5%) 40 (87.0%) 161(92.5%) 
Asian  2 (1.6%) 2 (4.4%) 4(2.3%) 
White  2 (1.6%) 2 (4.4%) 4(2.3%) 
Coloured  3 (2.3%) 1 (2.1%) 4(2.3%) 
Unknown   0 (0%) 1 (2.1%) 1(0.6) 
     
Alive   35 (27.3%) 18 (39.1%) 53 (30.5%) 
Dead  49 (38.3%) 9 (19.6%) 58(33.3%) 
Lost to follow up  44 (34.4%) 19 (41.3%) 63(36.2%) 
       
Mean age at diagnosis in 
years (S.D) 
 41.8 (13.0) 42.5 (13.2) 42 (13.1) 
Mean follow up duration 
in months (S.D) 
  67.1 (66.4) 62.1 (66.6) 65.8 (66.4) 
(F-female, M-male, DcSSc-diffuse cutaneous systemic sclerosis, LcSSc-limited cutaneous 
systemic sclerosis, SSc-systemic sclerosis) 
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3.3 Clinical and laboratory features 
Table 5 shows the frequency of clinical features at presentation and cumulative frequency. The 
most common clinical findings at onset for SSc were RP in 89.1% followed by arthralgias 
(64.4%) and digital ulcers (59.8%). With regards to the cumulative frequency, RP was the 
commonest feature (93.1%) followed by digital ulcers (71.3%) and arthralgia (74.1%). More 
than half of the patients had ILD (53.5%), while 35.1% had pulmonary hypertension. 
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Table 5: Summary of clinical features of patients at onset and cumulatively 
 Clinical features   
 
  
At onset n=174 (%) Cumulative n=174 (%) 
Raynaud’s phenomenon 155 (89.1%) 162 (93.1%) 
Digital ulcers 104 (59.8%) 124 (71.3%) 
Digital gangrene 4 (2.3%) 15 (8.6%) 
Telangiectasia 26 (14.9%) 55 (31.6%) 
Calcinosis 17 (9.8%) 41 (23.6%) 
Arthritis 42 (24.1%) 54 (31.0%) 
Arthralgia 112 (64.4%) 129 (74.1%) 
Joint contractures 25 (14.4%) 53 (30.5%) 
Myopathy 52 (29.9%) 66 (37.9%) 
Myositis 27 (15.5%) 35 (20.1%) 
Tendon friction rubs 8 (4.6%) 15 (8.6%) 
Interstitial lung disease 56 (32.2%) 93 (53.5%) 
Pulmonary hypertension 19 (10.9%) 61 (35.1%) 
Cor pulmonale 6 (3.4%) 30 (17.2%) 
Pleural effusion 2 (1.1%) 8 (4.6%) 
Pericardial effusion 9 (5.2%) 18 (10.3%) 
Serositis 11 (6.3%) 26 (14.9%) 
Pericarditis 1 (0.6%) 5 (2.9%) 
Hypertension 40 (23.0%) 66 (37.9%) 
Upper gastrointestinal 
symptoms 
112 (64.4%) 147 (84.5%) 
Lower gastrointestinal 
symptoms 
4 (2.3%) 18 (10.3%) 
Proteinuria 8 (4.6%) 42 (24.1%) 
Renal dysfunction 7 (4.0%) 27 (15.5%) 
Scleroderma renal crisis 2 (1.1%) 5 (2.9%) 
 
Table 6 shows the frequency of laboratory features at onset and cumulative frequencies. 
Anaemia was observed in 22.4% at onset and 54.0% overall. The ANA was positive in 85.1 % of 
patients, in whom the cumulative ACA positivity was 8.0%, and 20.7 % of patients for ATA. 
The cumulative frequencies of antibodies to RNP, Sm, Ro and La were 29.9%, 12.6%, 24.7% 
and 10.3% respectively. A high CRP was found in 58.6% and high ESR in 77.6% of patients.  
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Table 6: Summary of serological features of patients at onset and cumulative 
Serological Features 
 Onset Cumulative 
Anaemia( F<11,M<13) 39 (22.4%) 94 (54.0%) 
High ESR(>28) 74 (42.5%) 135 (77.6%) 
High CRP(>10) 47 (27.0%) 102 (58.6%) 
Low C3 4 (2.3%) 9 (5.2%) 
Low C4 13 (7.5%) 35 (20.1%) 
CK>140 51 (29.3%) 97 (55.7%) 
ANA 148 (85.1%) 148 (85.1%) 
ACA + 13 (7.5%) 14 (8.0%) 
AntiDsDna 2 (1.1%) 3 (1.7%) 
Anti-RNP 39 (22.4%) 52 (29.9%) 
Anti-Sm 18 (10.3%) 22 (12.6%) 
Anti-Ro 31 (17.8%) 43 (24.7%) 
Anti-La 12 (6.9%) 18 (10.3%) 
ATA 32 (18.4%) 36 (20.7%) 
Jo antibodies 1 (0.6%) 3 (1.7%) 
 F-female, M-male, ESR-erythrocyte sedimentation rate, CRP-C reactive protein, C3-
complement 3, C4-complement 4, CK-creatine kinase, ANA-antinuclear antibodies, ACA-
anticentromere antibodies, DsDNA-double stranded deoxyribose nucleic acid, RNP- 
antiribonucleoprotein antibodies, Sm- anti-Smith antibodies, Ro-antibodies to Ro protein, La-
antibodies to La protein, ATA- antibodies to topoisomerase 1, Jo antibodies-antibodies to 
antibody directed against the antihistidyl–tRNA synthetase.  
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Table 7: HIV and TB frequencies 
 Onset Cumulative 
HIV 7 (4.0%) 12 (6.9%) 
Pulmonary TB 2 (1.2%) 9 (5.2%) 
Extrapulmonary TB 0 (0%) 2 (1.1%) 
Overall TB 2 (1.2%) 11(6.3%) 
HIV-human immunodeficiency virus, TB-tuberculosis 
As shown in Table 7, the frequency of HIV in our cohort was 6.9%. The overall frequency of 
tuberculosis (TB) was 6.3% 
Drug therapy   
The most commonly used drugs were proton pump inhibitors (PPI) (71.8%), calcium channel 
blockers (CCB) (57.5%), ACEI (47.1%), steroids (46.0%) and cyclophosphamide (24.7%) 
(Table 8) 
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Table 8: Summary of drug therapy 
 
  All n=174(%) 
Corticosteroids 80 (46.0%) 
Cyclophosphamide 43 (24.7%) 
Azathioprine 26 (14.9%) 
Methotrexate 31 (17.8%) 
Mycophenolate mofetil  6 (3.4%) 
Iloprost 17 (9.8%) 
Omeprazole(PPI) 125 (71.8%) 
Angiotensin converting enzyme inhibitorsACEI 82 (47.1%) 
Calcium channel blockers 100 (57.5%) 
D-Penicillamine 30 (17.2%) 
Statin 23 (13.2%) 
Aspirin 22 (12.6%) 
PPI-proton pump inhibitors, ACEI-angiotensin converting enzyme inhibitors 
 3.4 Causes of death in SSc patients 
There were 58 known deaths recorded, representing a third of the total cohort. The causes of 
death are shown in Table 9 below. Of the known causes of death, 20 (34.5%) were deemed to be 
disease-related, and 8 (13.8%) to be disease-unrelated. Of the disease related deaths, majority 
was ILD/Cor pulmonale, 2 were from vascular complications, and 4 were from cardiac 
complications and only 1 patient died from SRC. Of the disease unrelated deaths, most were due 
to infections accounting for more than half of the deaths not related to SSc. In 30 cases, the cause 
of death was unknown but verified by hospital registrar and home affairs.  
 
 
 
 
26 
 
Table 9: Causes of known deaths in 58 patients 
 All SSc 
N=58 
DcSSc 
N=49 
LcSSc 
N=9 
Total Deaths 
Known cause of death 
Disease related 
 ILD/Cor Pulmonale 
               Isolated PAH 
              PH with ILD 
              ILD no PHT 
 Vascular involvement 
 Cardiac involvement 
 Renal involvement 
 
58/174 (33.3%) 
28/174 (16.0%) 
20 (71.4%) 
13 
1 
11 
1 
2 
4 
1 
49/128 (38.2%) 
24/128 (18.9%) 
17 (70.8%) 
11 
0 
11 
0 
1 
4 
1 
9/46 (19.6%) 
4/46 (8.7%) 
3(75.0%) 
2 
1 
0 
1 
1 
0 
0 
Disease unrelated 
 Malignancy 
 Infections 
 Others  
 
8(28.6%) 
2 
5 
1 
7(29.2%) 
1 
5 
1 
 
 
1(25.0%) 
1 
0 
0 
 
Unknown 30 (51.7%) 25(51.0%) 5(55.5%) 
SSc-systemic sclerosis, DcSSc-diffuse cutaneous systemic sclerosis, LcSSc-limited cutaneous 
systemic sclerosis, ILD- interstitial lung disease, PAH-pulmonary arterial hypertension, PH-
pulmonary hypertension  
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3.5 Kaplan Meier survival analysis  
The median overall survival rate of patients with SSc censored for those lost to follow up was at 
56.3 % and 35.8 % at 5 years and 10years respectively. As shown in Table 10, univariate cox 
regression analysis showed significant differences in worse survival rates for patients with high 
CRP, upper GIT symptoms, cor pulmonale/pulmonary hypertension, renal dysfunction and 
proteinuria. The survival outcome was worse in DcSSc compared to LcSSc. However, this did 
not reach statistical difference with a p-value of 0.14 (Figure 4). Statistical significance in 
outcomes was seen in patients with digital ulcers compared to those who did not have digital 
ulcer with p-value 0.0368 (Figure 5). The former were were also associated with a worse 
survival outcome. There was difference in survival outcome between patients with ILD 
compared to without ILD (Figure 10). The presence of telangiectasia was assoicated with a better 
outcome. 
 
Figure 4: Overall survival in SSc 
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Figure 5: Overall survival by disease subtype (p=0.14) 
 
Figure 6: Overall survival with or without digital ulcers (P=0.04) 
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Figure 7: Overall survival with and without telangiectasia (P=0.04) 
 
Figure 8: Overall survival with or without upper GIT symptoms (P=0.04) 
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Figure 9: Overall survival with or without high CRP (P=0.01) 
 
Figure 10: Overall survival of with or without proteinuria (P=0.01) 
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Figure 11: Overall survival with or without interstitial lung disease (P=0.96) 
 
Figure 12: Overall survival with or without cor pulmonale / pulmonary hypertension 
(p=0.01) 
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3.6 Predictors of mortality in SSc patients 
Univariate cox analysis was performed, this is shown in Table 10. This demonstrated a high 
hazard ratio of statistical significance in patients with digital ulcer (HR 2.27), Telangiectasia 
(HR0.54), Cor pulmonale, pulmonary hypertension (HR 2.10), Serositis (HR30.6), proteinuria 
(HR2.08), renal dysfunction (HR2.99) and a high CRP (HR 2.47). 
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Table 10: Summary of Univariate Cox regression modelling for prognostic factors for 
mortality in SSc 
  Hazard. 
Ratio 
p-
value 
[95% Conf. 
Interval] 
Gender 1.24 0.601 0.56 2.73 
Race 0.59 0.378 0.18 1.90 
Age of onset of symptoms 1.01 0.429 0.99 1.03 
Smoker 0.86 0.572 0.52 1.44 
Raynaud’s phenomenon 1.13 0.864 0.28 4.65 
Digital ulcers 2.27 0.043 1.03 5.02 
Digital gangrene 1.10 0.809 0.50 2.44 
Telangiectasia 0.54 0.038 0.30 0.97 
Calcinosis 1.06 0.850 0.59 1.89 
Arthritis 0.83 0.499 0.48 1.43 
Joint contractures 0.98 0.938 0.57 1.68 
Myositis 0.79 0.478 0.41 1.51 
Tendon friction rubs 1.02 0.971 0.40 2.60 
Interstitial lung disease 0.99 0.960 0.57 1.71 
Cor Pulmonale/Pulmonary 
Hypertension 
2.10 0.008 1.22 3.63 
Serositis (pericardial and pleural 
effusion) 
30.59 0.000 5.93 157.68 
Hypertension 0.68 0.175 0.40 1.18 
Upper GIT symptoms 6.03 0.075 0.83 43.68 
Proteinuria 2.08 0.011 1.18 3.66 
Renal dysfunction 2.99 0.000 1.65 5.40 
SRC 3.23 0.053 0.98 10.62 
Anaemia 0.99 0.967 0.57 1.70 
High ESR 1.04 0.921 0.45 2.45 
High CRP>10 2.47 0.008 1.27 4.80 
LowC3 andC4 0.99 0.982 0.53 1.87 
Sm 0.96 0.920 0.43 2.14 
Ro 0.72 0.337 0.37 1.40 
La 1.13 0.772 0.50 2.52 
HIV 2.14 0.120 0.82 5.60 
 
GIT-gastrointestinal tract, SRC-scleroderma renal crisis, ESR-erythrocyte sedimentation rate, 
CRP- C reactive protein, C3- complement 3, C4-complement 4, Sm- antibodies against Smith 
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protein, Ro- antibodies against Ro protein , La- antibodies against La protein , HIV- human 
immunodeficiency virus 
CHAPTER FOUR: DISCUSSION AND CONCLUSIONS 
This record review represents one of the only studies on deaths and causes thereof in SSc in Sub-
Saharan Africa.  
4.1 Demographics 
In this study of predominantly black South Africans, the subset distribution was predominantly 
DcSSc (73.6%), which differs from that reported in Caucasians where the predominant subset 
was LcSSc. (Hesselstrand, Scheja et al. 1998, Strickland, Pauling et al. 2013). These racial 
differences are consistent with findings in US studies where DcSSc was seen more in women of 
African American descent compared to Caucasian women (Laing, Gillespie et al. 1997).   
The female to male ratio of 6.9:1 is higher than the (ratio) reported in a recent Egyptian 
study.(Moneima, Darweesha et al. 2013), but similar to that reported in the UK of 7:1 
(Strickland, Pauling et al. 2013). The mean age at diagnosis of 42 years; is a younger age than 
that reported in UK, Spain, Taiwan and Denmark (Jacobsen, Halberg et al. 1998, Joven, 
Almodovar et al. 2010, Kuo, See et al. 2011, Strickland, Pauling et al. 2013). 
 
4.2 Clinical features 
The most common clinical feature was Raynaud’s phenomenon, found in 93.1% of patients, and 
is similar to that reported in other studies(Meier, Frommer et al. 2012). Digital ulcers were 
observed in 59.8% at onset, which is numerically higher than the 36% observed in the EUSTAR 
cohort of predominantly Caucasian patients (Meier, Frommer et al. 2012). The cumulative 
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frequency of ILD (53.5%) is similar to that reported previously in a local study (56%) (Tager and 
Tikly 1999), and in African American with SSc (54%) (Steen, Domsic et al. 2012). 
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4.3 Serological features 
All except 14.9 % of patients tested positive for the ANA. Antinuclear antibody negative SSc is a 
well-known and described phenomenon with a reported frequency of 5-16% (Steen 2005). 
Anticentromere antibody) was positive in only 8% of our patients, in agreement with 7.5% 
observed by Ashmore from the same institution(Ashmore, Tikly et al. 2018), and lower than that 
reported in Caucasians. This in part, is a reflection of the relative smaller proportion of patients 
in the present study having LcSSc, which is commonly associated with AC (Walker, Tyndall et 
al. 2007). Antitopoisomerase antibody was found in about a fifth of patients and is usually 
associated with diffuse disease and a poorer prognosis (Grassegger, Pohla-Gubo et al. 2008). The 
high percentage of patients with antiRNP antibodies is comparable to that reported in a previous 
study done in the United States of America (Nietert, Mitchell et al. 2006) 
4.4 Deaths 
The majority of the known causes of death in the present study were disease-related, and 
cardiopulmonary complications were the leading cause of death, similar to findings in other 
populations. (Tyndall, Bannert et al. 2010, Rubio-Rivas, Royo et al. 2014). Cardiopulmonary 
complications are known to carry a higher risk of death compared to other systemic 
manifestations (Komocsi, Vorobcsuk et al. 2012). Noteworthy is that only one patient in our 
study died due to SRC. This is in part due to the early use of ACEI in patients with SRC, which 
has been shown to reduce SRC related deaths significantly over the past 3 decades (Steen and 
Medsger 2007). In spite of our best efforts to determine the causes of death in all patients by 
examining mortuary records and Department of Home Affairs records, we were unable to 
determine the cause of the death in about half of the patients.  We suspect that one of the reasons 
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for this was that most of these patients died at home, and the specific cause of death was not 
recorded by the attending health care professional. 
4.5 Survival  
As observed in several studies previously, DcSSc carried a worse prognosis than LcSSc. Of 
interest is that there was no difference in survival in patients with ILD compared to patients 
without ILD. This is similar to that seen in a South African study that focused specifically on  
ILD in SSc (Ashmore 2014). 
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4.6 Predictors for mortality 
Several clinical features were associated with death. The risk for death was increased in patients 
with digital ulcers, Cor pulmonale, pulmonary hypertension, serositis, proteinuria, renal 
dysfunction and a high CRP. Serositis followed by renal dysfuction and digital ulcers conferred 
the highest risk for death. Although only a minority of patients have serositis in SSc, like our 
findings, this has also been found in a Spanish study (Joven, Almodovar et al. 2010). Similarly, 
renal dysfunction has also been reported as a predictor of death in Hungarian patients (Czirjak, 
Kumanovics et al. 2008). Surprisingly, telangiectasia was found to be protective. Telangiectasiae 
are a feature of long standing disease (Varga  
2013), and are associated with pulmonary arterial hypertension and thus seen as  a surrogate 
marker for small vessel disease (Shah, Wigley et al. 2010).  
 4.7 Limitations of the study 
There are several limitations to the study. Inherent to most retrospective studies is the problem of 
missing data. Moreover, a large number of patients were lost to follow up making it difficult and 
almost impossible to ascertain whether they were alive or dead. Furthermore as indicated earlier 
in more than half the cases we were unable to ascertain the cause of death as these deaths 
occurred outside of the hospital. 
4.8 Conclusion 
In this retrospective review of mainly black South Africans with DcSSc, the majority of known 
deaths were disease-related and in particular due to ILD and Cor pulmonale. Predictors of death 
included serositis, proteinuria, renal dysfunction and a high CRP. Earlier and more effective 
medical interventions for cardiopulmonary complications are likely to reduce mortality in this 
disease that carries a dismal prognosis. 
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APPENDIX A: SCLERODERMA RESEARCH DATA SHEET 
 
Study number: 
Age: 
 
Sex : M F 
  
Age of onset of symptoms : ________ 
Ethnic 
origin : 
B W A C Date or Age of Diagnosis : ________ 
Smoker : Y N 
    
 
Alive on 31/12/2015 : Y N 
 
Outcome : 
   
Dead Alive  Unknown Lost to follow up 
 
Follow-up duration in months till 31/12/2015: 
 
Subsets Limited Diffuse Overlap   
  
  
  
Skin 
 
  
  
Raynaud’s phenomenon 0 1 2   
Digital Ulcers 0 1 2   
Digital gangrene 0 1 2   
Telangiectasia 0 1 2   
Calcinosis 0 1 2   
     
Modified Rodnan Score              
    
Score at diagnosis:      
    
Highest Score:                                              
    
     
Musculoskeletal 
    
Arthritis 0 1 2   
Arthralgia 0 1 2   
Joint contractures 0 1 2   
Myopathy 0 1 2   
Myositis 0 1 2   
Tendon friction rubs 0 1 2   
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Cardio Respiratory 
    
Interstitial lung disease 
 
  
  
 
At 
Diagnosis  
Last 
Reading   
Clinical     
  
x-ray changes     
  
DLCO     
  
FVC predicted %     
  
FEV1 / FVC     
  
HRCT     
  
  
  
  
Pulmonary hypertension 0 1 2   
Cor pulmonale Y N 
  
  
  
  
Serositis 
 
  
  
Pleural effusion 0 1 2   
Pericarditis 0 1 2   
Pericardial effusion 0 1 2   
Hypertension 0 1 2   
  
  
  
GIT `   
  
Upper GIT symptoms 0 1 2   
Lower GIT symptoms 0 1 2   
 
  
  
  
Renal 
 
  
  
Proteinuria 0 1 2   
Renal dysfunction 0 1 2   
Scleroderma renal crisis 0 1 2   
 
  
  
  
Lab Results 
 
  
  
Anaemia 0 1 2   
High ESR 0 1 2   
High CRP 0 1 2   
Low C3 0 1 2   
Low C4 0 1 2   
High CK 0 1 2   
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ANA- highest titre + 
pattern  
 
  
dsDNA 0 1 2   
RNP 0 1 2   
Sm 0 1 2   
Ro 0 1 2   
La 0 1 2   
ATA 0 1 2   
Jo antibodies 0 1 2   
HIV 0 1 2   
Pulmonary TB 0 1 2   
Extrapulmonary TB 0 1 2   
 
Cause of death 
 
Directly caused by scleroderma    
  
Indirectly caused by scleroderma    
  
Not caused by scleroderma    
 
 SSc related death  
 
 Pulmonary 
   
   
    
Interstitial lung disease Y N 
 Pulmonary arterial hypertension Y N 
 Others Y N 
 
 
   Cardiac 
     
   Arrhythmias Y N 
 Left heart failure Y N 
 Right heart failure Y N 
 Pericarditis Y N 
 
 
   Renal 
   
 
   Renal crisis Y N    
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Gastrointestinal Y N 
 
Infections 
  
 
 
   Pneumonia Y N 
 Septicaemia Y N 
 Others Y N 
 
 
   Malignancy 
   
 
   Non-small cell lung cancer Y N 
 Small cell lung cancer Y N 
 Others Y N 
 
 
   Cardiovascular 
   
 
   Myocardial infarction  Y N 
 Pulmonary Embolism Y N 
 Stroke Y N 
 
 
   Others Y N 
 Unknown Y N 
 
 
   
 
   
Treatment Route 
Average 
dose 
duration 
    
Steroids 
   
Cyclophosphamide    
Methotrexate 
   
Azathioprine 
   
Mycophenolate mofetil 
   
Iloprost 
   
 
   History of use of other drugs 
   Calcium channel blockers Y N 
 ACEI/ARB Y N 
 Statin Y N 
 Aspirin Y N 
 Proton pump inhibitors Y N 
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Data sheet definitions 
0- Not present 
1- Present at diagnosis 
2- Developed later in illness, after diagnosis 
 
Skin 
Raynaud’s - Vasospasm resulting in pallor (white), cyanosis (blue) and/or hyperaemia (red) 
Fingertip ulcers- ulcers distal to or at proximal interphalangeal joint not thought to be due to 
trauma 
Fingertip pitting scars – depressed areas at digital tips as a result of ischaemia rather than trauma 
or exogenous causes 
Digital gangrene 
Modified Rodnan skin score 
 Score at onset 
            Highest score 
Telangiectasia – Visible capillaries that blanch on pressure 
       Especially on the face and inside the mouth or skin  
Calcinosis- Areas of calcium deposition 
 
Musculoskeletal 
Arthritis-documented synovitis 
Arthralgia- painful joints  
Joint contractures/deformities- Fixed flexion deformities or contractures due to tightening of skin 
Myopathy- proximal muscle weakness. 
Myositis- Peter Bowen’s criteria         clinical myopathy 
Raised CK 
     EMG changes 
     Muscle biopsy proven 
Cardiorespiratory 
Interstitial lung disease -   Clinical- Bibasal Velcro crackles 
 Chest X ray changes- basal interstitial/fibrotic changes 
 HRCT- honey combing, ground opacification, reticulonodular opacities, traction 
bronchiectasis 
 Lung functions- first and last reading if possible 
 
Pulmonary hypertension-        pulmonary artery pressures >40mmHg on echocardiogram 
    Specific ECG changes- right ventricular hypertrophy   
        And P pulmonale 
Hypertension-BP>140/90 > 2 occasions 
 
Serositis 
Pleural effusion- Tapped and not infective 
Pericarditis- Confirmed on echo/ ECG 
Pericardial effusion- confirmed on echo 
 
Renal 
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Proteinuria- 1+ protein or more on dipstick 
Renal dysfunction- Urea>8mmol/L, Creatinine>100umol/L 
Scleroderma renal crisis- Rapidly progressive renal failure, usually high BP, high creatinine, 
proteinuria and microscopic haematuria 
  
GIT 
Upper symptoms- heartburn, regurgitation, dysphagia, oesophagitis 
Lower symptoms- diarrhoea, constipation, malabsorption, abdominal pain or distension 
 
Lab results 
All abnormal results present more than 50% of the time 
Anaemia- male Hb <13g/dL/ 
       Female Hb<11g/dL 
High ESR>28 
High CRP>10 
Low C3    0,500- 1,530/ 0.90-1.80  
Low C4    0,200- 1,000 /0.10-0.40  
High CK> 140 
 
All antibodies- 0, 1, 2 
Drugs-0, 1, 2. 
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APPENDIX B:  ACR 1980 CLASSIFICATION CRITERIA  
Criterion Definition 
Major criterion Proximal scleroderma 
Or 2 or more of the following  
Minor criteria Sclerodactyly 
Digital pitting scars of the fingertips or loss of 
substance of the distal finger pad 
Bilateral basilar pulmonary fibrosis 
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APPENDIX C: ACR/EULAR 2013 CLASSIFICATION CRITERIA 
Item Sub-item Score 
Skin thickening of  the 
fingers of both hands 
extending proximal to the 
metacarpophalangeal joints 
 9 
Skin thickening of the 
fingers 
Puffy fingers 
Sclerodactyly 
2 
4 
Fingertip lesions Digital tip ulcers 
Fingertip pitting scars 
2 
3 
Telangiectasia  2 
Abnormal nail fold 
capillaries 
 2 
Pulmonary arterial 
hypertension and/or 
interstitial lung disease 
Pulmonary arterial 
hypertension 
Interstitial lung disease 
2 
 
2 
Raynaud’s phenomenon  3 
SSc related autoantibodies Anticentromere 
Anti-topoisomerase I 
Anti-RNA polymerase III 
 
3 
 
A score of equal or more than 9 is diagnostic of SSc 
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APPENDIX D: ETHICAL CLEARANCE CERTIFICATE 
 
